# FDA Approves Furoscix ReadyFlow Autoinjector for Heart Failure and CKD Edema

> fda · REPORTED · 2026-07-24

On July 23-24, 2026, the FDA approved MannKind's Furoscix ReadyFlow, the first and only autoinjector delivering IV-equivalent furosemide diuretic therapy for edema in adults with heart failure or chronic kidney disease, reducing administration time from five hours to under 10 seconds. MannKind simultaneously announced a $50 million private placement led by Frazier Life Sciences to fund the associated $45 million contingent value rights payment and general corporate purposes.

About MannKind Corporation: MannKind Corporation is a biopharmaceutical company focused on transforming chronic disease care through innovative patient-centric solutions, including inhaled insulin and subcutaneous drug delivery devices.

- Company: MannKind Corporation
- Sector: cardiology
- Primary source: https://www.biospace.com/press-releases/mannkind-announces-fda-approval-of-furoscix-readyflow-the-first-and-only-autoinjector-delivering-iv-equivalent-diuretic-therapy-for-the-treatment-of-edema-in-adults-with-heart-failure-or-chronic-kidney-disease

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.